English

ARRAY BIOPHARMA INC

EDGAR

Quarterly report (10-Q) · filed 2019-05-07

163 filing records in this dataset, filed from 2001-02-13 to 2019-05-07. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

35.4 million USD

2018 Q4 · USD

Exact inputs and evidence

Revenue: 35437000 USD Source

Operating margin

-132.49%

2018 Q4 · %

Exact inputs and evidence

Operating Income: -129927000 USD Source
Operating Income: -82978000 USD Source
Revenue: 35437000 USD Source

Operating cash flow

-28.6 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -119783000 USD Source
Operating Cash Flow: -91154000 USD Source

Free cash flow

-28.7 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -119783000 USD Source
Operating Cash Flow: -91154000 USD Source
Capital Expenditure: 1232000 USD Source
Capital Expenditure: 1122000 USD Source

Cash and cash equivalents: 96.6 million USD 2019-03-31 Source
Exact value

96636000 USD
Long-term debt including current maturities: 134 million USD 2019-03-31 Source
Exact value

134245000 USD
Shares outstanding: 222 million shares 2019-03-31 Source
Exact value

221548492 shares

Reported share-count change

5.25% · 11 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

210503949 shares · 2018-03-31· Source
221548492 shares · 2019-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

174 million USD

2017-07-01 – 2018-06-30

Exact inputs and evidence

Revenue: 29746000 USD · 2017-07-01 – 2017-09-30 Source
Revenue: 42218000 USD · 2017-10-01 – 2017-12-31 Source
Revenue: 66367000 USD · 2018-01-01 – 2018-03-31 Source
Revenue: 35437000 USD · 2018-04-01 – 2018-06-30 Source

Net income

-126 million USD

2018-04-01 – 2019-03-31

Exact inputs and evidence

Net income: -52448000 USD · 2018-04-01 – 2018-06-30 Source
Net income: -24811000 USD · 2018-07-01 – 2018-09-30 Source
Net income: -11362000 USD · 2018-10-01 – 2018-12-31 Source
Net income: -37494000 USD · 2019-01-01 – 2019-03-31 Source

Operating cash flow

-116 million USD

2018-04-01 – 2019-03-31

Exact inputs and evidence

Operating cash flow: -119783000 USD · 2017-07-01 – 2018-06-30 Source
Operating cash flow: -91154000 USD · 2017-07-01 – 2018-03-31 Source
Operating cash flow: -34800000 USD · 2018-07-01 – 2018-09-30 Source
Operating cash flow: -43438000 USD · 2018-07-01 – 2018-12-31 Source
Operating cash flow: -34800000 USD · 2018-07-01 – 2018-09-30 Source
Operating cash flow: -87426000 USD · 2018-07-01 – 2019-03-31 Source
Operating cash flow: -43438000 USD · 2018-07-01 – 2018-12-31 Source

Capital expenditure

1.57 million USD

2018-04-01 – 2019-03-31

Exact inputs and evidence

Capital expenditure: 1232000 USD · 2017-07-01 – 2018-06-30 Source
Capital expenditure: 1122000 USD · 2017-07-01 – 2018-03-31 Source
Capital expenditure: 265000 USD · 2018-07-01 – 2018-09-30 Source
Capital expenditure: 843000 USD · 2018-07-01 – 2018-12-31 Source
Capital expenditure: 265000 USD · 2018-07-01 – 2018-09-30 Source
Capital expenditure: 1455000 USD · 2018-07-01 – 2019-03-31 Source
Capital expenditure: 843000 USD · 2018-07-01 – 2018-12-31 Source

Free cash flow

-118 million USD

2018-04-01 – 2019-03-31

Exact inputs and evidence

Operating cash flow: -119783000 USD · 2017-07-01 – 2018-06-30 Source
Operating cash flow: -91154000 USD · 2017-07-01 – 2018-03-31 Source
Operating cash flow: -34800000 USD · 2018-07-01 – 2018-09-30 Source
Operating cash flow: -43438000 USD · 2018-07-01 – 2018-12-31 Source
Operating cash flow: -34800000 USD · 2018-07-01 – 2018-09-30 Source
Operating cash flow: -87426000 USD · 2018-07-01 – 2019-03-31 Source
Operating cash flow: -43438000 USD · 2018-07-01 – 2018-12-31 Source
Capital expenditure: 1232000 USD · 2017-07-01 – 2018-06-30 Source
Capital expenditure: 1122000 USD · 2017-07-01 – 2018-03-31 Source
Capital expenditure: 265000 USD · 2018-07-01 – 2018-09-30 Source
Capital expenditure: 843000 USD · 2018-07-01 – 2018-12-31 Source
Capital expenditure: 265000 USD · 2018-07-01 – 2018-09-30 Source
Capital expenditure: 1455000 USD · 2018-07-01 – 2019-03-31 Source
Capital expenditure: 843000 USD · 2018-07-01 – 2018-12-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-05-07.

Financial data available through: 2018-06-30.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2018-06-30
Operating income: 11 of 11 periods available· newest 2018-06-30
Net income: 11 of 11 periods available· newest 2018-06-30
Operating cash flow: 11 of 11 periods available· newest 2018-06-30
Capital expenditure: 9 of 11 periods available· newest 2018-06-30
Total assets: 11 of 11 periods available· newest 2018-06-30
Total liabilities: 11 of 11 periods available· newest 2018-06-30
Current assets: 11 of 11 periods available· newest 2018-06-30
Current liabilities: 11 of 11 periods available· newest 2018-06-30
Cash and cash equivalents: 11 of 11 periods available· newest 2018-06-30
Long-term debt including current maturities: 5 of 11 periods available· newest 2018-06-30
Shares outstanding: 8 of 11 periods available· newest 2018-06-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+15.2%

Prior period

USD 150.85 million

2016-07-01 – 2017-06-30
Current period

USD 173.77 million

2017-07-01 – 2018-06-30

Exact inputs and evidence

173768000 − 150852000 = 22916000 USD

150852000 USD · 2016-07-01 – 2017-06-30
Inspect prior input Prior source
173768000 USD · 2017-07-01 – 2018-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Year-over-year change in Revenue: 22916000 USD Concept: fundies:Revenue Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 173768000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#437950 Filing: 000110041218000026 Input fundies:Revenue: 150852000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#434978 Filing: 000110041218000026
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 30.5 million

Prior period

−USD 116.8 million

2016-07-01 – 2017-06-30
Current period

−USD 147.3 million

2017-07-01 – 2018-06-30

Exact inputs and evidence

-147300000 − -116800000 = -30500000 USD

-116800000 USD · 2016-07-01 – 2017-06-30
Inspect prior input Prior source
-147300000 USD · 2017-07-01 – 2018-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Year-over-year change in Net income: -30500000 USD Concept: fundies:NetIncome Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -147300000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#398863 Filing: 000110041218000026 Input fundies:NetIncome: -116800000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#397713 Filing: 000110041218000026
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 80.43 million

Prior period

−USD 39.35 million

2016-07-01 – 2017-06-30
Current period

−USD 119.78 million

2017-07-01 – 2018-06-30

Exact inputs and evidence

-119783000 − -39354000 = -80429000 USD

-39354000 USD · 2016-07-01 – 2017-06-30
Inspect prior input Prior source
-119783000 USD · 2017-07-01 – 2018-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Year-over-year change in Operating cash flow: -80429000 USD Concept: fundies:OperatingCashFlow Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -119783000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#396198 Filing: 000110041218000026 Input fundies:OperatingCashFlow: -39354000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#395986 Filing: 000110041218000026
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-65%

Prior period

USD 3.52 million

2016-07-01 – 2017-06-30
Current period

USD 1.23 million

2017-07-01 – 2018-06-30

Exact inputs and evidence

1232000 − 3520000 = -2288000 USD

3520000 USD · 2016-07-01 – 2017-06-30
Inspect prior input Prior source
1232000 USD · 2017-07-01 – 2018-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Year-over-year change in Capital expenditure: -2288000 USD Concept: fundies:CapitalExpenditure Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1232000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415782 Filing: 000110041218000026 Input fundies:CapitalExpenditure: 3520000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415572 Filing: 000110041218000026
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2017-07-01 – 2018-06-30

Revenue USD 173.77 million 100% of revenue
Operating costs Derived USD 303.7 million 175% of revenue
Operating income −USD 129.93 million −75% of revenue
Tax, interest and other Derived USD 17.37 million 10% of revenue
Net income −USD 147.3 million −85% of revenue

Cash

Operating cash flow −USD 119.78 million −69% of revenue
Capital expenditure USD 1.23 million 0.7% of revenue
Free cash flow Derived −USD 121.02 million −70% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2009 Operating loss: operating costs were 510% of revenue.
2010 Operating loss: operating costs were 219% of revenue.
2011 Operating loss: operating costs were 151% of revenue.
2012 Operating loss: operating costs were 113% of revenue.
2013 Operating loss: operating costs were 157% of revenue.
2014 Operating loss: operating costs were 280% of revenue.
2015 Net income was higher than operating income, so the split is not drawn.
2016 Operating loss: operating costs were 160% of revenue.
2017 Operating loss: operating costs were 168% of revenue.
2018 Operating loss: operating costs were 175% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2009 2008-07-01 – 2009-06-30	24982000	127435000 Derived	-102453000	25362000 Derived	-127815000	Unavailable	Source 2008-07-01 – 2009-06-30: 24982000 USD Inspect Revenue Open source 2008-07-01 – 2009-06-30: -102453000 USD Inspect Operating Income Open source 2008-07-01 – 2009-06-30: -127815000 USD Inspect Net Income Open source 2008-07-01 – 2009-06-30: -92939000 USD Inspect Operating Cash Flow Open source
2010 2009-07-01 – 2010-06-30	53880000	117931000 Derived	-64051000	13549000 Derived	-77600000	16633000 Derived	Source 2009-07-01 – 2010-06-30: 53880000 USD Inspect Revenue Open source 2009-07-01 – 2010-06-30: -64051000 USD Inspect Operating Income Open source 2009-07-01 – 2010-06-30: -77600000 USD Inspect Net Income Open source 2009-07-01 – 2010-06-30: 17886000 USD Inspect Operating Cash Flow Open source 2009-07-01 – 2010-06-30: 1253000 USD Inspect Capital Expenditure Open source
2011 2010-07-01 – 2011-06-30	71901000	108675000 Derived	-36774000	19526000 Derived	-56300000	-67863000 Derived	Source 2010-07-01 – 2011-06-30: 71901000 USD Inspect Revenue Open source 2010-07-01 – 2011-06-30: -36774000 USD Inspect Operating Income Open source 2010-07-01 – 2011-06-30: -56300000 USD Inspect Net Income Open source 2010-07-01 – 2011-06-30: -65962000 USD Inspect Operating Cash Flow Open source 2010-07-01 – 2011-06-30: 1901000 USD Inspect Capital Expenditure Open source
2012 2011-07-01 – 2012-06-30	85135000	96182000 Derived	-11047000	12553000 Derived	-23600000	-34983000 Derived	Source 2011-07-01 – 2012-06-30: 85135000 USD Inspect Revenue Open source 2011-07-01 – 2012-06-30: -11047000 USD Inspect Operating Income Open source 2011-07-01 – 2012-06-30: -23600000 USD Inspect Net Income Open source 2011-07-01 – 2012-06-30: -33546000 USD Inspect Operating Cash Flow Open source 2011-07-01 – 2012-06-30: 1437000 USD Inspect Capital Expenditure Open source
2013 2012-07-01 – 2013-06-30	69580000	109122000 Derived	-39542000	22358000 Derived	-61900000	-89407000 Derived	Source 2012-07-01 – 2013-06-30: 69580000 USD Inspect Revenue Open source 2012-07-01 – 2013-06-30: -39542000 USD Inspect Operating Income Open source 2012-07-01 – 2013-06-30: -61900000 USD Inspect Net Income Open source 2012-07-01 – 2013-06-30: -87067000 USD Inspect Operating Cash Flow Open source 2012-07-01 – 2013-06-30: 2340000 USD Inspect Capital Expenditure Open source
2014 2013-07-01 – 2014-06-30	42078000	117696000 Derived	-75618000	9682000 Derived	-85300000	-74296000 Derived	Source 2013-07-01 – 2014-06-30: 42078000 USD Inspect Revenue Open source 2013-07-01 – 2014-06-30: -75618000 USD Inspect Operating Income Open source 2013-07-01 – 2014-06-30: -85300000 USD Inspect Net Income Open source 2013-07-01 – 2014-06-30: -71682000 USD Inspect Operating Cash Flow Open source 2013-07-01 – 2014-06-30: 2614000 USD Inspect Capital Expenditure Open source
2015 2014-07-01 – 2015-06-30	51909000	48616000 Derived	3293000	-6107000 Derived	9400000	-8300000 Derived	Source 2014-07-01 – 2015-06-30: 51909000 USD Inspect Revenue Open source 2014-07-01 – 2015-06-30: 3293000 USD Inspect Operating Income Open source 2014-07-01 – 2015-06-30: 9400000 USD Inspect Net Income Open source 2014-07-01 – 2015-06-30: -5793000 USD Inspect Operating Cash Flow Open source 2014-07-01 – 2015-06-30: 2507000 USD Inspect Capital Expenditure Open source
2016 2015-07-01 – 2016-06-30	137879000	220088000 Derived	-82209000	10631000 Derived	-92840000	-73249000 Derived	Source 2015-07-01 – 2016-06-30: 137879000 USD Inspect Revenue Open source 2015-07-01 – 2016-06-30: -82209000 USD Inspect Operating Income Open source 2015-07-01 – 2016-06-30: -92840000 USD Inspect Net Income Open source 2015-07-01 – 2016-06-30: -70090000 USD Inspect Operating Cash Flow Open source 2015-07-01 – 2016-06-30: 3159000 USD Inspect Capital Expenditure Open source
2017 2016-07-01 – 2017-06-30	150852000	252930000 Derived	-102078000	14722000 Derived	-116800000	-42874000 Derived	Source 2016-07-01 – 2017-06-30: 150852000 USD Inspect Revenue Open source 2016-07-01 – 2017-06-30: -102078000 USD Inspect Operating Income Open source 2016-07-01 – 2017-06-30: -116800000 USD Inspect Net Income Open source 2016-07-01 – 2017-06-30: -39354000 USD Inspect Operating Cash Flow Open source 2016-07-01 – 2017-06-30: 3520000 USD Inspect Capital Expenditure Open source
2018 2017-07-01 – 2018-06-30	173768000	303695000 Derived	-129927000	17373000 Derived	-147300000	-121015000 Derived	Source 2017-07-01 – 2018-06-30: 173768000 USD Inspect Revenue Open source 2017-07-01 – 2018-06-30: -129927000 USD Inspect Operating Income Open source 2017-07-01 – 2018-06-30: -147300000 USD Inspect Net Income Open source 2017-07-01 – 2018-06-30: -119783000 USD Inspect Operating Cash Flow Open source 2017-07-01 – 2018-06-30: 1232000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 173.8M 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-06-30	Revenue	24982000	Revenue: 24982000 Open source
20102010-06-30	Revenue	53880000	Revenue: 53880000 Open source
20112011-06-30	Revenue	71901000	Revenue: 71901000 Open source
20122012-06-30	Revenue	85135000	Revenue: 85135000 Open source
20132013-06-30	Revenue	69580000	Revenue: 69580000 Open source
20142014-06-30	Revenue	42078000	Revenue: 42078000 Open source
20152015-06-30	Revenue	51909000	Revenue: 51909000 Open source
20162016-06-30	Revenue	137879000	Revenue: 137879000 Open source
20172017-06-30	Revenue	150852000	Revenue: 150852000 Open source
20182018-06-30	Revenue	173768000	Revenue: 173768000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

15.2% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Year over year	-13.3%	Revenue: 24982000 Open source Revenue: 28808000 Open source
20102010-06-30	Year over year	115.7%	Revenue: 53880000 Open source Revenue: 24982000 Open source
20112011-06-30	Year over year	33.4%	Revenue: 71901000 Open source Revenue: 53880000 Open source
20122012-06-30	Year over year	18.4%	Revenue: 85135000 Open source Revenue: 71901000 Open source
20132013-06-30	Year over year	-18.3%	Revenue: 69580000 Open source Revenue: 85135000 Open source
20142014-06-30	Year over year	-39.5%	Revenue: 42078000 Open source Revenue: 69580000 Open source
20152015-06-30	Year over year	23.4%	Revenue: 51909000 Open source Revenue: 42078000 Open source
20162016-06-30	Year over year	165.6%	Revenue: 137879000 Open source Revenue: 51909000 Open source
20172017-06-30	Year over year	9.4%	Revenue: 150852000 Open source Revenue: 137879000 Open source
20182018-06-30	Year over year	15.2%	Revenue: 173768000 Open source Revenue: 150852000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -74.8% 2018

Net margin -84.8% 2018

Free cash flow margin -69.6% 2018

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Operating margin	-410.1%	Operating Income: -102453000 Open source Revenue: 24982000 Open source
20102010-06-30	Operating margin	-118.9%	Operating Income: -64051000 Open source Revenue: 53880000 Open source
20112011-06-30	Operating margin	-51.1%	Operating Income: -36774000 Open source Revenue: 71901000 Open source
20122012-06-30	Operating margin	-13%	Operating Income: -11047000 Open source Revenue: 85135000 Open source
20132013-06-30	Operating margin	-56.8%	Operating Income: -39542000 Open source Revenue: 69580000 Open source
20142014-06-30	Operating margin	-179.7%	Operating Income: -75618000 Open source Revenue: 42078000 Open source
20152015-06-30	Operating margin	6.3%	Operating Income: 3293000 Open source Revenue: 51909000 Open source
20162016-06-30	Operating margin	-59.6%	Operating Income: -82209000 Open source Revenue: 137879000 Open source
20172017-06-30	Operating margin	-67.7%	Operating Income: -102078000 Open source Revenue: 150852000 Open source
20182018-06-30	Operating margin	-74.8%	Operating Income: -129927000 Open source Revenue: 173768000 Open source
20092009-06-30	Net margin	-511.6%	Net Income: -127815000 Open source Revenue: 24982000 Open source
20102010-06-30	Net margin	-144%	Net Income: -77600000 Open source Revenue: 53880000 Open source
20112011-06-30	Net margin	-78.3%	Net Income: -56300000 Open source Revenue: 71901000 Open source
20122012-06-30	Net margin	-27.7%	Net Income: -23600000 Open source Revenue: 85135000 Open source
20132013-06-30	Net margin	-89%	Net Income: -61900000 Open source Revenue: 69580000 Open source
20142014-06-30	Net margin	-202.7%	Net Income: -85300000 Open source Revenue: 42078000 Open source
20152015-06-30	Net margin	18.1%	Net Income: 9400000 Open source Revenue: 51909000 Open source
20162016-06-30	Net margin	-67.3%	Net Income: -92840000 Open source Revenue: 137879000 Open source
20172017-06-30	Net margin	-77.4%	Net Income: -116800000 Open source Revenue: 150852000 Open source
20182018-06-30	Net margin	-84.8%	Net Income: -147300000 Open source Revenue: 173768000 Open source
20092009-06-30	Free cash flow margin	Not reported	Revenue: 24982000 Open source Operating Cash Flow: -92939000 Open source
20102010-06-30	Free cash flow margin	30.9%	Revenue: 53880000 Open source Operating Cash Flow: 17886000 Open source Capital Expenditure: 1253000 Open source
20112011-06-30	Free cash flow margin	-94.4%	Revenue: 71901000 Open source Operating Cash Flow: -65962000 Open source Capital Expenditure: 1901000 Open source
20122012-06-30	Free cash flow margin	-41.1%	Revenue: 85135000 Open source Operating Cash Flow: -33546000 Open source Capital Expenditure: 1437000 Open source
20132013-06-30	Free cash flow margin	-128.5%	Revenue: 69580000 Open source Operating Cash Flow: -87067000 Open source Capital Expenditure: 2340000 Open source
20142014-06-30	Free cash flow margin	-176.6%	Revenue: 42078000 Open source Operating Cash Flow: -71682000 Open source Capital Expenditure: 2614000 Open source
20152015-06-30	Free cash flow margin	-16%	Revenue: 51909000 Open source Operating Cash Flow: -5793000 Open source Capital Expenditure: 2507000 Open source
20162016-06-30	Free cash flow margin	-53.1%	Revenue: 137879000 Open source Operating Cash Flow: -70090000 Open source Capital Expenditure: 3159000 Open source
20172017-06-30	Free cash flow margin	-28.4%	Revenue: 150852000 Open source Operating Cash Flow: -39354000 Open source Capital Expenditure: 3520000 Open source
20182018-06-30	Free cash flow margin	-69.6%	Revenue: 173768000 Open source Operating Cash Flow: -119783000 Open source Capital Expenditure: 1232000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -119.8M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-06-30	Operating cash flow	-92939000	Operating Cash Flow: -92939000 Open source
20102010-06-30	Operating cash flow	17886000	Operating Cash Flow: 17886000 Open source
20112011-06-30	Operating cash flow	-65962000	Operating Cash Flow: -65962000 Open source
20122012-06-30	Operating cash flow	-33546000	Operating Cash Flow: -33546000 Open source
20132013-06-30	Operating cash flow	-87067000	Operating Cash Flow: -87067000 Open source
20142014-06-30	Operating cash flow	-71682000	Operating Cash Flow: -71682000 Open source
20152015-06-30	Operating cash flow	-5793000	Operating Cash Flow: -5793000 Open source
20162016-06-30	Operating cash flow	-70090000	Operating Cash Flow: -70090000 Open source
20172017-06-30	Operating cash flow	-39354000	Operating Cash Flow: -39354000 Open source
20182018-06-30	Operating cash flow	-119783000	Operating Cash Flow: -119783000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -121M 2018

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-06-30	Free cash flow	Unavailable	Operating Cash Flow: -92939000 Open source
20102010-06-30	Free cash flow	16633000	Operating Cash Flow: 17886000 Open source Capital Expenditure: 1253000 Open source
20112011-06-30	Free cash flow	-67863000	Operating Cash Flow: -65962000 Open source Capital Expenditure: 1901000 Open source
20122012-06-30	Free cash flow	-34983000	Operating Cash Flow: -33546000 Open source Capital Expenditure: 1437000 Open source
20132013-06-30	Free cash flow	-89407000	Operating Cash Flow: -87067000 Open source Capital Expenditure: 2340000 Open source
20142014-06-30	Free cash flow	-74296000	Operating Cash Flow: -71682000 Open source Capital Expenditure: 2614000 Open source
20152015-06-30	Free cash flow	-8300000	Operating Cash Flow: -5793000 Open source Capital Expenditure: 2507000 Open source
20162016-06-30	Free cash flow	-73249000	Operating Cash Flow: -70090000 Open source Capital Expenditure: 3159000 Open source
20172017-06-30	Free cash flow	-42874000	Operating Cash Flow: -39354000 Open source Capital Expenditure: 3520000 Open source
20182018-06-30	Free cash flow	-121015000	Operating Cash Flow: -119783000 Open source Capital Expenditure: 1232000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

52.3% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Liabilities / assets	177.5%	Total Liabilities: 168756000 Open source Total Assets: 95055000 Open source
20102010-06-30	Liabilities / assets	173.3%	Total Liabilities: 275857000 Open source Total Assets: 159179000 Open source
20112011-06-30	Liabilities / assets	246.4%	Total Liabilities: 220232000 Open source Total Assets: 89374000 Open source
20122012-06-30	Liabilities / assets	179.4%	Total Liabilities: 193879000 Open source Total Assets: 108073000 Open source
20132013-06-30	Liabilities / assets	116.1%	Total Liabilities: 157897000 Open source Total Assets: 135988000 Open source
20142014-06-30	Liabilities / assets	118.8%	Total Liabilities: 162346000 Open source Total Assets: 136625000 Open source
20152015-06-30	Liabilities / assets	78.5%	Total Liabilities: 155554000 Open source Total Assets: 198207000 Open source
20162016-06-30	Liabilities / assets	122.5%	Total Liabilities: 206832000 Open source Total Assets: 168900000 Open source
20172017-06-30	Liabilities / assets	95.8%	Total Liabilities: 267418000 Open source Total Assets: 279145000 Open source
20182018-06-30	Liabilities / assets	52.3%	Total Liabilities: 240621000 Open source Total Assets: 460364000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.71× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Current assets / current liabilities	0.89×	Current Assets: 44917000 Open source Current Liabilities: 50295000 Open source
20102010-06-30	Current assets / current liabilities	1.51×	Current Assets: 117298000 Open source Current Liabilities: 77931000 Open source
20112011-06-30	Current assets / current liabilities	1.01×	Current Assets: 70562000 Open source Current Liabilities: 69808000 Open source
20122012-06-30	Current assets / current liabilities	1.23×	Current Assets: 93107000 Open source Current Liabilities: 75936000 Open source
20132013-06-30	Current assets / current liabilities	2.4×	Current Assets: 121309000 Open source Current Liabilities: 50577000 Open source
20142014-06-30	Current assets / current liabilities	2.31×	Current Assets: 121676000 Open source Current Liabilities: 52733000 Open source
20152015-06-30	Current assets / current liabilities	4.5×	Current Assets: 191047000 Open source Current Liabilities: 42424000 Open source
20162016-06-30	Current assets / current liabilities	2.96×	Current Assets: 155301000 Open source Current Liabilities: 52434000 Open source
20172017-06-30	Current assets / current liabilities	3.88×	Current Assets: 270177000 Open source Current Liabilities: 69551000 Open source
20182018-06-30	Current assets / current liabilities	4.71×	Current Assets: 451543000 Open source Current Liabilities: 95931000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2009 2008-07-01 – 2009-06-30	−USD 127.82 million Exact value Exact value: -127815000 USD 2008-07-01 – 2009-06-30: -127815000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2009-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -127815000 USD Concept: fundies:NetIncome Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:NetIncome: -127815000 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/0001047469-11-007339.txt#12075 The citation records this snapshot. The page link may show a newer release later.	−USD 92.94 million Exact value Exact value: -92939000 USD 2008-07-01 – 2009-06-30: -92939000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2009-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -92939000 USD Concept: fundies:OperatingCashFlow Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -92939000 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/0001047469-11-007339.txt#12315 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2010 2009-07-01 – 2010-06-30	−USD 77.6 million Exact value Exact value: -77600000 USD 2009-07-01 – 2010-06-30: -77600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2010-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -77600000 USD Concept: fundies:NetIncome Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:NetIncome: -77600000 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041213000007/arry-20130331.xml#590063 Filing: 000110041213000007 The citation records this snapshot. The page link may show a newer release later.	USD 17.89 million Exact value Exact value: 17886000 USD 2009-07-01 – 2010-06-30: 17886000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2010-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: 17886000 USD Concept: fundies:OperatingCashFlow Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 17886000 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000104746912008381/arry-20120630.xml#809125 Filing: 000104746912008381 The citation records this snapshot. The page link may show a newer release later.	USD 1.25 million Exact value Exact value: 1253000 USD 2009-07-01 – 2010-06-30: 1253000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2010-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 1253000 USD Concept: fundies:CapitalExpenditure Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1253000 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000104746912008381/arry-20120630.xml#809514 Filing: 000104746912008381 The citation records this snapshot. The page link may show a newer release later.	USD 16.63 million Calculation and evidence 17886000 − 1253000 USD Exact free cash flow: 16633000 USD 2009-07-01 – 2010-06-30: 17886000 USD · Inspect Operating Cash Flow · Source 2009-07-01 – 2010-06-30: 1253000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2010-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: 16633000 USD Concept: free-cash-flow Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 17886000 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000104746912008381/arry-20120630.xml#809125 Filing: 000104746912008381 Input fundies:CapitalExpenditure: 1253000 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000104746912008381/arry-20120630.xml#809514 Filing: 000104746912008381 The citation records this snapshot. The page link may show a newer release later.
2011 2010-07-01 – 2011-06-30	−USD 56.3 million Exact value Exact value: -56300000 USD 2010-07-01 – 2011-06-30: -56300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2011-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -56300000 USD Concept: fundies:NetIncome Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:NetIncome: -56300000 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041214000026/arry-20140331.xml#440957 Filing: 000110041214000026 The citation records this snapshot. The page link may show a newer release later.	−USD 65.96 million Exact value Exact value: -65962000 USD 2010-07-01 – 2011-06-30: -65962000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2011-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -65962000 USD Concept: fundies:OperatingCashFlow Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -65962000 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041213000025/arry-20130630.xml#822828 Filing: 000110041213000025 The citation records this snapshot. The page link may show a newer release later.	USD 1.9 million Exact value Exact value: 1901000 USD 2010-07-01 – 2011-06-30: 1901000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2011-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 1901000 USD Concept: fundies:CapitalExpenditure Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1901000 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041213000025/arry-20130630.xml#938275 Filing: 000110041213000025 The citation records this snapshot. The page link may show a newer release later.	−USD 67.86 million Calculation and evidence -65962000 − 1901000 USD Exact free cash flow: -67863000 USD 2010-07-01 – 2011-06-30: -65962000 USD · Inspect Operating Cash Flow · Source 2010-07-01 – 2011-06-30: 1901000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2011-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -67863000 USD Concept: free-cash-flow Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -65962000 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041213000025/arry-20130630.xml#822828 Filing: 000110041213000025 Input fundies:CapitalExpenditure: 1901000 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041213000025/arry-20130630.xml#938275 Filing: 000110041213000025 The citation records this snapshot. The page link may show a newer release later.
2012 2011-07-01 – 2012-06-30	−USD 23.6 million Exact value Exact value: -23600000 USD 2011-07-01 – 2012-06-30: -23600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2012-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -23600000 USD Concept: fundies:NetIncome Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:NetIncome: -23600000 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041215000018/arry-20150331.xml#277495 Filing: 000110041215000018 The citation records this snapshot. The page link may show a newer release later.	−USD 33.55 million Exact value Exact value: -33546000 USD 2011-07-01 – 2012-06-30: -33546000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2012-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -33546000 USD Concept: fundies:OperatingCashFlow Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33546000 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041214000048/arry-20140630.xml#698334 Filing: 000110041214000048 The citation records this snapshot. The page link may show a newer release later.	USD 1.44 million Exact value Exact value: 1437000 USD 2011-07-01 – 2012-06-30: 1437000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2012-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 1437000 USD Concept: fundies:CapitalExpenditure Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1437000 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041214000048/arry-20140630.xml#820106 Filing: 000110041214000048 The citation records this snapshot. The page link may show a newer release later.	−USD 34.98 million Calculation and evidence -33546000 − 1437000 USD Exact free cash flow: -34983000 USD 2011-07-01 – 2012-06-30: -33546000 USD · Inspect Operating Cash Flow · Source 2011-07-01 – 2012-06-30: 1437000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2012-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -34983000 USD Concept: free-cash-flow Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33546000 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041214000048/arry-20140630.xml#698334 Filing: 000110041214000048 Input fundies:CapitalExpenditure: 1437000 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041214000048/arry-20140630.xml#820106 Filing: 000110041214000048 The citation records this snapshot. The page link may show a newer release later.
2013 2012-07-01 – 2013-06-30	−USD 61.9 million Exact value Exact value: -61900000 USD 2012-07-01 – 2013-06-30: -61900000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2013-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -61900000 USD Concept: fundies:NetIncome Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:NetIncome: -61900000 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041215000040/arry-20150930.xml#167054 Filing: 000110041215000040 The citation records this snapshot. The page link may show a newer release later.	−USD 87.07 million Exact value Exact value: -87067000 USD 2012-07-01 – 2013-06-30: -87067000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2013-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -87067000 USD Concept: fundies:OperatingCashFlow Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -87067000 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041215000023/arry-20150630.xml#335909 Filing: 000110041215000023 The citation records this snapshot. The page link may show a newer release later.	USD 2.34 million Exact value Exact value: 2340000 USD 2012-07-01 – 2013-06-30: 2340000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2013-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 2340000 USD Concept: fundies:CapitalExpenditure Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2340000 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041215000023/arry-20150630.xml#350438 Filing: 000110041215000023 The citation records this snapshot. The page link may show a newer release later.	−USD 89.41 million Calculation and evidence -87067000 − 2340000 USD Exact free cash flow: -89407000 USD 2012-07-01 – 2013-06-30: -87067000 USD · Inspect Operating Cash Flow · Source 2012-07-01 – 2013-06-30: 2340000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2013-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -89407000 USD Concept: free-cash-flow Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -87067000 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041215000023/arry-20150630.xml#335909 Filing: 000110041215000023 Input fundies:CapitalExpenditure: 2340000 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041215000023/arry-20150630.xml#350438 Filing: 000110041215000023 The citation records this snapshot. The page link may show a newer release later.
2014 2013-07-01 – 2014-06-30	−USD 85.3 million Exact value Exact value: -85300000 USD 2013-07-01 – 2014-06-30: -85300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2014-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -85300000 USD Concept: fundies:NetIncome Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:NetIncome: -85300000 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041217000006/arry-20170331.xml#310499 Filing: 000110041217000006 The citation records this snapshot. The page link may show a newer release later.	−USD 71.68 million Exact value Exact value: -71682000 USD 2013-07-01 – 2014-06-30: -71682000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2014-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -71682000 USD Concept: fundies:OperatingCashFlow Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -71682000 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041216000048/arry-20160630.xml#361121 Filing: 000110041216000048 The citation records this snapshot. The page link may show a newer release later.	USD 2.61 million Exact value Exact value: 2614000 USD 2013-07-01 – 2014-06-30: 2614000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2014-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 2614000 USD Concept: fundies:CapitalExpenditure Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2614000 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041216000048/arry-20160630.xml#376326 Filing: 000110041216000048 The citation records this snapshot. The page link may show a newer release later.	−USD 74.3 million Calculation and evidence -71682000 − 2614000 USD Exact free cash flow: -74296000 USD 2013-07-01 – 2014-06-30: -71682000 USD · Inspect Operating Cash Flow · Source 2013-07-01 – 2014-06-30: 2614000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2014-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -74296000 USD Concept: free-cash-flow Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -71682000 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041216000048/arry-20160630.xml#361121 Filing: 000110041216000048 Input fundies:CapitalExpenditure: 2614000 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041216000048/arry-20160630.xml#376326 Filing: 000110041216000048 The citation records this snapshot. The page link may show a newer release later.
2015 2014-07-01 – 2015-06-30	USD 9.4 million Exact value Exact value: 9400000 USD 2014-07-01 – 2015-06-30: 9400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2015-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: 9400000 USD Concept: fundies:NetIncome Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2015-06-30&surface=latest&period_type=duration&start=2014-07-01&unit=USD&dimensions= Input fundies:NetIncome: 9400000 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000007/arry-20180331.xml#354770 Filing: 000110041218000007 The citation records this snapshot. The page link may show a newer release later.	−USD 5.79 million Exact value Exact value: -5793000 USD 2014-07-01 – 2015-06-30: -5793000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2015-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -5793000 USD Concept: fundies:OperatingCashFlow Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2015-06-30&surface=latest&period_type=duration&start=2014-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5793000 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000162828017008555/arry-20170630.xml#448922 Filing: 000162828017008555 The citation records this snapshot. The page link may show a newer release later.	USD 2.51 million Exact value Exact value: 2507000 USD 2014-07-01 – 2015-06-30: 2507000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2015-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 2507000 USD Concept: fundies:CapitalExpenditure Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2015-06-30&surface=latest&period_type=duration&start=2014-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2507000 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000162828017008555/arry-20170630.xml#466520 Filing: 000162828017008555 The citation records this snapshot. The page link may show a newer release later.	−USD 8.3 million Calculation and evidence -5793000 − 2507000 USD Exact free cash flow: -8300000 USD 2014-07-01 – 2015-06-30: -5793000 USD · Inspect Operating Cash Flow · Source 2014-07-01 – 2015-06-30: 2507000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2015-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -8300000 USD Concept: free-cash-flow Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5793000 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000162828017008555/arry-20170630.xml#448922 Filing: 000162828017008555 Input fundies:CapitalExpenditure: 2507000 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000162828017008555/arry-20170630.xml#466520 Filing: 000162828017008555 The citation records this snapshot. The page link may show a newer release later.
2016 2015-07-01 – 2016-06-30	−USD 92.84 million Exact value Exact value: -92840000 USD 2015-07-01 – 2016-06-30: -92840000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2016-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -92840000 USD Concept: fundies:NetIncome Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:NetIncome: -92840000 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#396565 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	−USD 70.09 million Exact value Exact value: -70090000 USD 2015-07-01 – 2016-06-30: -70090000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2016-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -70090000 USD Concept: fundies:OperatingCashFlow Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70090000 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#395774 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	USD 3.16 million Exact value Exact value: 3159000 USD 2015-07-01 – 2016-06-30: 3159000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2016-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 3159000 USD Concept: fundies:CapitalExpenditure Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3159000 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415362 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	−USD 73.25 million Calculation and evidence -70090000 − 3159000 USD Exact free cash flow: -73249000 USD 2015-07-01 – 2016-06-30: -70090000 USD · Inspect Operating Cash Flow · Source 2015-07-01 – 2016-06-30: 3159000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2016-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -73249000 USD Concept: free-cash-flow Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70090000 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#395774 Filing: 000110041218000026 Input fundies:CapitalExpenditure: 3159000 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415362 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.
2017 2016-07-01 – 2017-06-30	−USD 116.8 million Exact value Exact value: -116800000 USD 2016-07-01 – 2017-06-30: -116800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2017-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -116800000 USD Concept: fundies:NetIncome Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:NetIncome: -116800000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#397713 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	−USD 39.35 million Exact value Exact value: -39354000 USD 2016-07-01 – 2017-06-30: -39354000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2017-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -39354000 USD Concept: fundies:OperatingCashFlow Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39354000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#395986 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	USD 3.52 million Exact value Exact value: 3520000 USD 2016-07-01 – 2017-06-30: 3520000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2017-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 3520000 USD Concept: fundies:CapitalExpenditure Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3520000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415572 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	−USD 42.87 million Calculation and evidence -39354000 − 3520000 USD Exact free cash flow: -42874000 USD 2016-07-01 – 2017-06-30: -39354000 USD · Inspect Operating Cash Flow · Source 2016-07-01 – 2017-06-30: 3520000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2017-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -42874000 USD Concept: free-cash-flow Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39354000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#395986 Filing: 000110041218000026 Input fundies:CapitalExpenditure: 3520000 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415572 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.
2018 2017-07-01 – 2018-06-30	−USD 147.3 million Exact value Exact value: -147300000 USD 2017-07-01 – 2018-06-30: -147300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Net Income: -147300000 USD Concept: fundies:NetIncome Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ANetIncome&period=2018-06-30&surface=latest&period_type=duration&start=2017-07-01&unit=USD&dimensions= Input fundies:NetIncome: -147300000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#398863 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	−USD 119.78 million Exact value Exact value: -119783000 USD 2017-07-01 – 2018-06-30: -119783000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Operating Cash Flow: -119783000 USD Concept: fundies:OperatingCashFlow Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3AOperatingCashFlow&period=2018-06-30&surface=latest&period_type=duration&start=2017-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -119783000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#396198 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	USD 1.23 million Exact value Exact value: 1232000 USD 2017-07-01 – 2018-06-30: 1232000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Capital Expenditure: 1232000 USD Concept: fundies:CapitalExpenditure Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412/explain?concept=fundies%3ACapitalExpenditure&period=2018-06-30&surface=latest&period_type=duration&start=2017-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1232000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415782 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.	−USD 121.02 million Calculation and evidence -119783000 − 1232000 USD Exact free cash flow: -121015000 USD 2017-07-01 – 2018-06-30: -119783000 USD · Inspect Operating Cash Flow · Source 2017-07-01 – 2018-06-30: 1232000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARRAY BIOPHARMA INC · 2018-06-30 ARRAY BIOPHARMA INC (edgar:1100412) Free cash flow: -121015000 USD Concept: free-cash-flow Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T07:45:11Z Snapshot: 0f71741f1b503c01b771fcaa9c40ae8b237dd9da639e9e65e1b71d9326abb6e4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1100412?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -119783000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#396198 Filing: 000110041218000026 Input fundies:CapitalExpenditure: 1232000 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1100412/000110041218000026/arry-20180630.xml#415782 Filing: 000110041218000026 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

163 filings · 2,462 latest values · 2,462 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001100412, 1100412, edgar:1100412

Also known as ARRAY BIOPHARMA INC

ARRAY BIOPHARMA INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2018 2017-07-01 – 2018-06-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation